PHOTOCURE ASA (PHO.OL) Stock Fundamental Analysis
OSL:PHO - Euronext Oslo - NO0010000045 - Common Stock - Currency: NOK
PHO gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 50 industry peers in the Pharmaceuticals industry. PHO has a great financial health rating, but its profitability evaluates not so good. PHO is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PHO has reported negative net income.
In the past year PHO had a positive cash flow from operations.
In the past 5 years PHO reported 4 times negative net income.
Of the past 5 years PHO 4 years had a positive operating cash flow.
1.2 Ratios
The Return On Assets of PHO (-0.45%) is worse than 60.00% of its industry peers.
PHO has a Return On Equity of -0.67%. This is in the lower half of the industry: PHO underperforms 60.00% of its industry peers.
Looking at the Return On Invested Capital, with a value of 2.47%, PHO is doing worse than 60.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.45% | ||
| ROE | -0.67% | ||
| ROIC | 2.47% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Operating Margin, with a value of 3.88%, PHO is doing worse than 60.00% of the companies in the same industry.
In the last couple of years the Operating Margin of PHO has declined.
Looking at the Gross Margin, with a value of 94.15%, PHO belongs to the top of the industry, outperforming 94.00% of the companies in the same industry.
In the last couple of years the Gross Margin of PHO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.88% | ||
| PM (TTM) | N/A | ||
| GM | 94.15% |
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
2. Health
2.1 Basic Checks
PHO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
PHO has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, PHO has more shares outstanding
Compared to 1 year ago, PHO has an improved debt to assets ratio.
2.2 Solvency
PHO has an Altman-Z score of 5.06. This indicates that PHO is financially healthy and has little risk of bankruptcy at the moment.
PHO has a better Altman-Z score (5.06) than 80.00% of its industry peers.
There is no outstanding debt for PHO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.24 | ||
| Altman-Z | 5.06 |
ROIC/WACC0.29
WACC8.57%
2.3 Liquidity
A Current Ratio of 4.08 indicates that PHO has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.08, PHO belongs to the top of the industry, outperforming 94.00% of the companies in the same industry.
A Quick Ratio of 3.70 indicates that PHO has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 3.70, PHO belongs to the best of the industry, outperforming 92.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.08 | ||
| Quick Ratio | 3.7 |
3. Growth
3.1 Past
PHO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1900.00%.
Looking at the last year, PHO shows a small growth in Revenue. The Revenue has grown by 4.94% in the last year.
Measured over the past years, PHO shows a quite strong growth in Revenue. The Revenue has been growing by 13.29% on average per year.
EPS 1Y (TTM)-1900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-145.65%
Revenue 1Y (TTM)4.94%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%12.67%
3.2 Future
PHO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 190.44% yearly.
PHO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.98% yearly.
EPS Next Y896.78%
EPS Next 2Y264.59%
EPS Next 3Y190.44%
EPS Next 5YN/A
Revenue Next Year14.48%
Revenue Next 2Y12.39%
Revenue Next 3Y12.83%
Revenue Next 5Y14.98%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PHO. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 36.47, the valuation of PHO can be described as expensive.
64.00% of the companies in the same industry are cheaper than PHO, based on the Price/Forward Earnings ratio.
PHO is valuated expensively when we compare the Price/Forward Earnings ratio to 20.74, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 36.47 |
4.2 Price Multiples
60.00% of the companies in the same industry are cheaper than PHO, based on the Enterprise Value to EBITDA ratio.
PHO's Price/Free Cash Flow ratio is a bit cheaper when compared to the industry. PHO is cheaper than 62.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.72 | ||
| EV/EBITDA | 24.23 |
4.3 Compensation for Growth
PHO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PHO's earnings are expected to grow with 190.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y264.59%
EPS Next 3Y190.44%
5. Dividend
5.1 Amount
PHO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
OSL:PHO (5/6/2025, 3:49:37 PM)
52.3
-1.9 (-3.51%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners50.48%
Inst Owner ChangeN/A
Ins Owners1.94%
Ins Owner ChangeN/A
Market Cap1.42B
Analysts82.5
Price Target83.13 (58.95%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-78.07%
Min EPS beat(2)-203.96%
Max EPS beat(2)47.82%
EPS beat(4)1
Avg EPS beat(4)-43.34%
Min EPS beat(4)-203.96%
Max EPS beat(4)47.82%
EPS beat(8)5
Avg EPS beat(8)41.71%
EPS beat(12)5
Avg EPS beat(12)-16.18%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.39%
Min Revenue beat(2)-2.17%
Max Revenue beat(2)1.4%
Revenue beat(4)2
Avg Revenue beat(4)-2.32%
Min Revenue beat(4)-9.78%
Max Revenue beat(4)1.4%
Revenue beat(8)4
Avg Revenue beat(8)-2.8%
Revenue beat(12)6
Avg Revenue beat(12)-3.28%
Revenue beat(16)8
Avg Revenue beat(16)-3.9%
PT rev (1m)-2.98%
PT rev (3m)-18.3%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)-205%
EPS NY rev (1m)33.02%
EPS NY rev (3m)5.45%
Revenue NQ rev (1m)-2.17%
Revenue NQ rev (3m)-1.54%
Revenue NY rev (1m)-0.13%
Revenue NY rev (3m)6.2%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 36.47 | ||
| P/S | 2.7 | ||
| P/FCF | 21.72 | ||
| P/OCF | 18.48 | ||
| P/B | 2.83 | ||
| P/tB | 5.42 | ||
| EV/EBITDA | 24.23 |
EPS(TTM)-0.18
EYN/A
EPS(NY)1.43
Fwd EY2.74%
FCF(TTM)2.41
FCFY4.6%
OCF(TTM)2.83
OCFY5.41%
SpS19.37
BVpS18.5
TBVpS9.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.45% | ||
| ROE | -0.67% | ||
| ROCE | 3.21% | ||
| ROIC | 2.47% | ||
| ROICexc | 4.6% | ||
| ROICexgc | 15.47% | ||
| OM | 3.88% | ||
| PM (TTM) | N/A | ||
| GM | 94.15% | ||
| FCFM | 12.43% |
ROA(3y)-3.44%
ROA(5y)-3.42%
ROE(3y)-5.33%
ROE(5y)-5.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-14.8%
ROICexc growth 3YN/A
ROICexc growth 5Y-32.88%
OM growth 3YN/A
OM growth 5Y-23.87%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.29%
GM growth 5Y0.46%
F-Score4
Asset Turnover0.71
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.24 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 39.75% | ||
| Cap/Sales | 2.18% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 156.01% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.08 | ||
| Quick Ratio | 3.7 | ||
| Altman-Z | 5.06 |
F-Score4
WACC8.57%
ROIC/WACC0.29
Cap/Depr(3y)33%
Cap/Depr(5y)196.94%
Cap/Sales(3y)1.85%
Cap/Sales(5y)14.41%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1900%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-145.65%
EPS Next Y896.78%
EPS Next 2Y264.59%
EPS Next 3Y190.44%
EPS Next 5YN/A
Revenue 1Y (TTM)4.94%
Revenue growth 3Y13.37%
Revenue growth 5Y13.29%
Sales Q2Q%12.67%
Revenue Next Year14.48%
Revenue Next 2Y12.39%
Revenue Next 3Y12.83%
Revenue Next 5Y14.98%
EBIT growth 1Y-26.64%
EBIT growth 3YN/A
EBIT growth 5Y-13.75%
EBIT Next Year172.2%
EBIT Next 3Y80%
EBIT Next 5YN/A
FCF growth 1Y81.38%
FCF growth 3Y47.91%
FCF growth 5Y27.04%
OCF growth 1Y58.87%
OCF growth 3Y47.56%
OCF growth 5Y30.02%